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The Nonsteroidal Farnesoid X Receptor 
Agonist Cilofexor (GS-9674) Improves 
Markers of Cholestasis and Liver Injury 
in Patients With Primary Sclerosing 
Cholangitis
Michael Trauner,1 Aliya Gulamhusein,2 Bilal Hameed,3 Stephen Caldwell,4 Mitchell L. Shiffman,5 Charles Landis,6 
Bertus Eksteen,7 Kosh Agarwal,8 Andrew Muir,9 Simon Rushbrook,10 Xiaomin Lu,11 Jun Xu,11 Jen-Chieh Chuang,11 
Andrew N. Billin,11 Georgia Li,11 Chuhan Chung,11 G. Mani Subramanian,11 Robert P. Myers,11 Christopher L. Bowlus,12 and  
Kris V. Kowdley13
Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-
controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X recep-
tor agonist in patients without cirrhosis with large-duct PSC. Patients were randomized to receive cilofexor 100 mg 
(n = 22), 30 mg (n = 20), or placebo (n = 10) orally once daily for 12 weeks. All patients had serum alkaline phos-
phatase (ALP) > 1.67 × upper limit of normal and total bilirubin ≤ 2 mg/dL at baseline. Safety, tolerability, phar-
macodynamic effects of cilofexor (serum C4 [7α-hydroxy-4-cholesten-3-one] and bile acids), and changes in liver 
biochemistry and serum fibrosis markers were evaluated. Overall, 52 patients were randomized (median age 
43 years, 58% male, 60% with inf lammatory bowel disease, 46% on ursodeoxycholic acid). Baseline median serum 
ALP and bilirubin were 348 U/L (interquartile range 288-439) and 0.7 mg/dL (0.5-1.0), respectively. Dose- 
dependent reductions in liver biochemistry were observed. At week 12, cilofexor 100 mg led to significant reductions 
in serum ALP (median reduction −21%; P  = 0.029 versus placebo), gamma-glutamyl transferase (−30%; P  < 0.001), 
alanine aminotransferase (ALT) (−49%; P  = 0.009), and aspartate aminotransferase (−42%; P  = 0.019). Cilofexor 
reduced serum C4 compared with placebo; reductions in bile acids were greatest with 100 mg. Relative reductions in 
ALP were similar between ursodeoxycholic acid–treated and untreated patients. At week 12, cilofexor-treated 
patients with a 25% or more relative reduction in ALP had greater reductions in serum alanine aminotransferase, 
aspartate aminotransferase, gamma-glutamyl transferase, tissue inhibitor of metalloproteinase 1, C-reactive protein, 
and bile acids than nonresponders. Adverse events were similar between cilofexor and placebo-treated patients. Rates 
of grade 2 or 3 pruritus were 14% with 100 mg, 20% with 30 mg, and 40% with placebo. Conclusion: In this 12-
week, randomized, placebo-controlled study, cilofexor was well tolerated and led to significant improvements in liver 
biochemistries and markers of cholestasis in patients with PSC. (Hepatology 2019;70:788-801).
Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver dis-ease whose pathogenesis remains poorly understood.(1) PSC is characterized histologically by chronic inflammation and fibro-obliterative destruc-tion of intrahepatic and/or extrahepatic bile ducts, 
Abbreviations: AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C4, 
7α-hydroxy-4-cholesten-3-one; CRP, C-reactive protein; CYP7A1, cholesterol 7-hydroxylase; ELF, Enhanced Liver Fibrosis; FGF19, fibroblast 
growth factor 19; FXR, farnesoid X receptor; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GGT, gamma-glutamyl transferase; 
HDL-C, high-density lipoprotein cholesterol; IBD, inflammatory bowel disease; IQR, interquartile range; LC/MS-MS, liquid chromatography–
tandem mass spectrometry; LDL-C, low-density lipoprotein cholesterol; MRCP, magnetic resonance cholangiopancreatography; PSC, primary 
sclerosing cholangitis; qd, once daily; TIMP-1, tissue inhibitor of metalloproteinase 1; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
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resulting in progressive biliary fibrosis and ultimately 
cirrhosis. Although various pharmacologic interven-
tions have been studied, no approved medical thera-
pies exist that have reduced rates of clinical outcomes 
such as hepatic decompensation, cholangiocarcinoma, 
transplantation, or mortality. Although ursodeoxy-
cholic acid (UDCA) is associated with improvement 
in biochemical markers of cholestasis, including a 
reduction in serum alkaline phosphatase (ALP), 
in most PSC patients, the clinical benefits of such 
responses remain unclear.(2-5) Recent analyses have 
identified lower baseline levels and/or improvements 
in ALP over time as important markers of improved 
prognosis.(6-9) However, a study of high-dose UDCA 
demonstrated worse clinical outcomes compared with 
placebo, despite reductions in serum ALP.(3) These 
seemingly contradictory findings illustrate the com-
plexity of identifying surrogate markers of clinical 
benefit in PSC and also highlight the major unmet 
need for novel therapies to treat this condition.
A hallmark of PSC is the presence of cholesta-
sis. Thus, one potential therapeutic target may be 
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activation of the farnesoid X receptor (FXR), a 
ligand-activated nuclear hormone receptor that is 
the key regulator of bile acid synthesis, conjugation, 
and excretion.(10,11) FXR is highly expressed in the 
liver, gallbladder, intestines, and kidney. Activation of 
FXR within the intestine by bile acids or FXR ago-
nists leads to release of fibroblast growth factor 19 
(FGF19), a key hormonal regulator of postprandial 
metabolism.(12,13) FGF19 travels to the liver through 
the portal circulation, binds to the FGFR4/βKlotho 
receptor complex, and activates a signaling cascade 
that results in the down-regulation of cholesterol 
7α-hydroxylase (CYP7A1) expression, thereby inhib-
iting the rate-limiting step in bile acid synthesis.(14) 
Direct activation of FXR in the liver can also regu-
late expression of a host of genes involved in bile acid 
metabolism. Specifically, FXR activation increases the 
expression of transporters responsible for canalicular 
and basolateral bile acid efflux, while inhibiting bile 
acid synthesis and basolateral bile acid uptake by 
hepatocytes. These multifaceted effects of FXR ago-
nism, both indirect through FGF19 induction and 
direct at the level of hepatocytes, suggest that FXR 
may be a feasible therapeutic target for mitigating the 
cholestasis characteristic of PSC.
In this 12-week, phase II, randomized, place-
bo-controlled study, we evaluated the safety and effi-
cacy of cilofexor (formerly GS-9674) in PSC patients 
without cirrhosis. Cilofexor is an oral, potent (EC50 
43 nM), and selective nonsteroidal FXR agonist that 
has demonstrated anti-inflammatory and antifibrotic 
effects and reduced portal pressure in preclinical mod-
els of liver fibrosis.(15) Here, we report that cilofexor 
had a favorable safety profile and led to significant 
reductions in serum ALP, other liver biochemistry 
tests, and markers of cholestasis in a dose-dependent 
fashion. Cilofexor was well tolerated, and impor-
tantly, did not exacerbate the pruritus characteristic of 
PSC. These findings indicate that cilofexor may have 
potential therapeutic benefit in patients with PSC.
Patients and Methods
StUDy popUlatIoN
Adult patients aged 18 to 70 years with a diag-
nosis of classic, large-duct PSC based on cholangio-
gram (magnetic resonance cholangiopancreatography 
[MRCP], endoscopic retrograde cholangiopancrea-
tography, or percutaneous transhepatic cholangio-
gram) within the previous 12 months were eligible. 
All patients had a serum ALP greater than 1.67 × 
the upper limit of normal (ULN), platelet count of 
150,000/mL3 or higher, serum albumin of 3.3 g/dL 
or more, and serum creatinine of less than or equal 
to ULN (≤1.14 mg/dL). Patients with a history of 
inflammatory bowel disease (IBD) were required to 
have a colonoscopy within 6 months of screening, 
demonstrating no evidence of active disease and a 
partial Mayo score of less than 2 with a score on the 
rectal bleeding domain of less than 1 during screening.
For patients on UDCA treatment, the dose of 
UDCA must have been stable for at least 12 months 
before screening and had to remain stable through 
the end of the treatment. In patients not on UDCA, 
there could be no UDCA use for at least 12 months 
before screening through the end of treatment. For 
patients receiving biologic treatments (e.g., antitumor 
necrosis factor or anti-integrin monoclonal antibod-
ies), immunosuppressants, or systemic corticosteroids, 
the dose had to be stable for at least 3 months before 
screening and anticipated to remain stable through-
out the trial. Exclusion criteria included histologic 
or imaging evidence of cirrhosis, previous history of 
decompensated liver disease, or a FibroSure/FibroTest 
(LabCorp, Burlington, NC) result of at least 0.75 
(unless a biopsy within 12 months excluded cirrhosis). 
Patients with alanine aminotransferase (ALT) greater 
than 10 × ULN, total bilirubin greater than 2 × ULN, 
or an international normalized ratio greater than 1.2 
were also excluded. Complete eligibility criteria are 
provided in the Supporting Information.
StUDy DeSIgN
In this multicenter, double-blind, randomized, pla-
cebo-controlled, phase II trial, eligible patients were 
randomized in a 2:2:1 ratio to receive treatment with 
cilofexor 100 mg orally once daily (qd), cilofexor 30 
mg qd, or placebo qd for 12 weeks (ClinicalTrials.
gov NCT02943460). Randomization was stratified by 
the presence or absence of UDCA treatment. After 
screening, study visits occurred at baseline and weeks 
1, 2, 4, 8, and 12 of treatment, and a follow-up visit 
4 weeks after discontinuing treatment. Patients who 
completed the 12-week blinded study phase with-
out permanently discontinuing the study drug were 
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eligible to participate in an optional, 96-week open- 
label extension phase, during which all patients were 
administered cilofexor 100 mg daily. In this manu-
script, we report findings from the 12-week blinded 
phase of the study.
aSSeSSMeNtS
Safety was evaluated by assessment of clinical lab-
oratory tests, physical examinations, and by documen-
tation of adverse events (AEs). All safety data were 
collected from the time of the first dose of study drug 
to 30 days after the last dose of study drug. MRCP was 
performed at baseline and read centrally by an expert 
radiologist.(16) Serum markers of liver injury and func-
tion including ALP, ALT, aspartate aminotransferase 
(AST), bilirubin, and gamma-glutamyl transferase 
(GGT) were assessed at baseline and weeks 1, 2, 4, 
8, and 12. Noninvasive markers of fibrosis, including 
the Enhanced Liver Fibrosis (ELF) test (Siemens, 
Tarrytown, NY) and its components (tissue inhibi-
tor of metalloproteinase 1 [TIMP-1], procollagen III 
N-terminal peptide [PIII-NP], and hyaluronic acid), 
and FibroSure/FibroTest were measured at baseline 
and week 12. Blood samples to evaluate the pharma-
codynamic effects of cilofexor were collected to assess 
changes in fasting plasma FGF19 and 7α-hydroxy-
4-cholesten-3-one (C4), an intermediate in the bio-
chemical synthesis of bile acids from cholesterol by 
CYP7A1. Total serum bile acids were measured by an 
enzymatic reaction (Covance, Princeton, NJ) at baseline 
and week 12. In addition, total, primary, and secondary 
bile acids were measured by liquid chromatography–
tandem mass spectrometry (LC/MS-MS) (Metabolon, 
Durham, NC) to assess the concentration of individual 
bile acid species. The contribution of UDCA and its 
conjugates to the bile acid pool were removed for these 
analyses. A fasting metabolic and lipid profile includ-
ing total cholesterol, low-density lipoprotein choles-
terol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), triglycerides, and glucose were collected 
at baseline and weeks 1, 4, 8, and 12. Liver stiffness 
by transient elastography (FibroScan; Echosens, Paris, 
France) was assessed at baseline and week 12.
StatIStICal aNalySeS
Given the exploratory nature of this study, a 
formal sample-size calculation was not performed. 
The planned number of patients was based on clin-
ical experience with similar phase II studies. Safety 
and efficacy were assessed in all patients who were 
randomized and received at least one dose of study 
drug. The primary endpoint of the study was the 
safety of cilofexor in patients with PSC, as evalu-
ated by examining the incidence of treatment-emer-
gent AEs, including serious adverse events (SAEs), 
and clinical laboratory tests. Exploratory efficacy 
endpoints included changes from baseline in serum 
ALP, GGT, ALT, AST, pharmacodynamic indica-
tors of FXR agonism (FGF19, C4, and total and 
primary bile acids), and noninvasive measures of 
fibrosis (ELF, FibroScan). The Wilcoxon rank sum 
test was used to compare changes from baseline in 
continuous parameters at week 12 between cilofex-
or-treated groups versus placebo. Univariate logistic 
regression was also used to explore baseline factors 
associated with ALP response, defined as at least a 
25% relative reduction from baseline to week 12 of 
therapy. An ALP reduction of this magnitude has 
been associated with a reduced risk of PSC-related 
clinical events during follow-up.(6) All statistical 
analyses were performed using SAS, version 9.4 
(SAS Institute Inc., Cary, NC).
StUDy oVeRSIgHt
The study was approved by the institutional 
review board or independent ethics committee at 
participating sites and conducted in compliance 
with the Declaration of Helsinki, Good Clinical 
Practice guidelines, and local regulatory require-
ments. Written informed consent was obtained 
from all patients prior to study initiation. The study 
was designed and conducted by the sponsor (Gilead 
Sciences) in collaboration with the principal inves-
tigator, according to the protocol. The sponsor col-
lected the data and elected to conduct an additional 
unplanned interim analysis with measures to ensure 
data integrity after all patients had discontinued or 
completed 12 weeks of study treatment. The spon-
sor also monitored study conduct and performed 
the statistical analyses. An independent data safety 
monitoring committee reviewed the progress of 
the study. All authors had access to the data and 
assumed responsibility for the integrity and com-
pleteness of the reported data. All authors reviewed 
and approved the final manuscript.
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Results
BaSelINe CHaRaCteRIStICS
Between November 29, 2016, and November 
9, 2017, a total of 105 patients were screened and 
52 patients were randomized and treated across 24 
sites in North America and Europe (United States, 
16; Canada, 3; United Kingdom, 4; and Austria, 1) 
(Supporting Fig. S1). Reasons for screen failure are 
provided in the Supporting Information. Overall, 
demographics and baseline characteristics were sim-
ilar between the treatment groups (Table 1). Most 
of the patients were male (58%); the median age was 
43 years (interquartile range [IQR] 35, 52); and 60% 
had concomitant IBD. Sixty percent of patients had 
intrahepatic and extrahepatic bile duct involvement 
on MRCP, and 46% were on UDCA. Median (IQR) 
serum ALP at baseline was 348 U/L (288, 439) or 
2.78 × ULN (2.29, 3.66), and serum bilirubin was 
taBle 1. Demographics and Baseline Characteristics
Cilofexor 100 mg
(n = 22)
Cilofexor 30 mg
(n = 20)
Placebo
(n = 10)
Total
(n = 52)
Demographics Age (years) 43 (36, 47) 46 (35, 57) 39 (33, 52) 43 (35, 52)
Male, n (%) 11 (50%) 14 (70%) 5 (50%) 30 (58%)
White, n (%) 17 (77%) 15 (75%) 7 (70%) 39 (75%)
Diabetes, n (%) 6 (27%) 2 (10%) 1 (10%) 9 (17%)
Weight (kg) 73.5 (67.5, 89.1) 79.8 (68.4, 95.9) 82.2 (63.0, 83.3) 77.9 (67.4, 88.6)
BMI (kg/m2) 25.8 (23.2, 30.3) 25.9 (22.8, 29.9) 25.8 (23.9, 29.6) 25.8 (23.2, 29.9)
IBD, n (%) 13 (59%) 11 (55%) 7 (70%) 31 (60%)
UDCA, n (%) 10 (46%) 9 (45%) 5 (50%) 24 (46%)
Liver biochemistry ALP (U/L) 350 (312, 387) 344 (271, 460) 380 (265, 547) 348 (288, 439)
ALP (× ULN) 2.87 (2.45, 3.51) 2.73 (2.15, 3.74) 3.31 (2.05, 4.33) 2.78 (2.29, 3.66)
GGT (U/L) 305 (192, 542) 564 (255, 910) 377 (224, 622) 423 (203, 628)
Total bilirubin (mg/dL) 0.6 (0.5, 1.1) 0.8 (0.6, 1.0) 0.6 (0.5, 0.9) 0.7 (0.5, 1.0)
ALT (U/L) 110 (83, 156) 119 (60, 197) 77 (59, 123) 109 (63, 156)
ALT (× ULN) 2.90 (1.92, 4.46) 3.01 (1.74, 4.81) 2.01 (1.60, 2.86) 2.67 (1.70, 4.12)
AST (U/L) 67 (52, 98) 75 (44, 104) 59 (47, 76) 64 (47, 99)
AST (× ULN) 1.92 (1.49, 2.87) 2.11 (1.29, 2.90) 1.74 (1.31, 2.10) 1.83 (1.34, 2.78)
Albumin (g/dL) 4.4 (4.2, 4.5) 4.5 (4.2, 4.7) 4.6 (4.2, 4.7) 4.4 (4.2, 4.7)
Fibrosis and 
inflammation
ELF 9.26 (8.73, 9.66) 9.77 (9.26, 10.31) 9.09 (8.87, 9.60) 9.38 (8.91, 9.88)
FibroTest 0.29 (0.27, 0.44) 0.47 (0.39, 0.57) 0.34 (0.23, 0.51) 0.40 (0.28, 0.51)
CRP (ug/mL) 0.27 (0.15, 0.51) 0.26 (0.10, 0.73) 0.19 (0.12, 0.46) 0.25 (0.13, 0.57)
Liver stiffness by FibroScan (kPa) 7.3 (6.2, 10.6) 10.1 (6.9, 12.5) 9.8 (7.9, 10.1) 9.4 (6.8, 10.6)
Bile acid 
homeostasis
FGF19 (pg/mL) 102 (66, 171) 118 (61, 174) 115 (107, 156) 112 (66, 168)
C4 (ng/mL) 10.4 (5.1, 23.5) 18.7 (9.8, 30.0) 18.9 (9.3, 27.1) 13.2 (7.3, 27.1)
Total bile acids by enzymatic assay (umol/L)* 19.6 (10.3, 33.1) 15.3 (9.4, 32.2) 13.7 (6.4, 17.0) 16.9 (9.6, 30.7)
Total bile acids by LC-MS/MS (ng/ml)* 5601.6 (2886.8, 
12787.3)
5424.4 (2381.3, 
12245.1)
5042.0 (1580.6, 
5622.2)
5169.6 (2509.7, 
10772.8)
Duct involvement 
on MRCP†
Intrahepatic and extrahepatic ducts 11 (50%) 14 (70%) 6 (60%) 31 (60%)
Intrahepatic ducts only 8 (36%) 4 (20%) 3 (30%) 15 (29%)
Normal biliary tree 2 (9%) 0 0 2 (4%)
Metabolism Glucose (mg/dL) 87 (81, 98) 87 (82, 94) 84 (79, 90) 87 (82, 96)
Cholesterol (mg/dL) 209 (178, 256) 240 (200, 274) 219 (188, 258) 218 (184, 263)
LDL-C (mg/dL) 111 (87, 132) 139 (102, 166) 123 (94, 153) 122 (94, 153)
HDL-C (mg/dL) 82 (64, 97) 75 (64, 86) 75 (58, 87) 77 (63, 91)
All data are median (IQR) or n (%).
*Serum total bile acids include UDCA and conjugates.
†Baseline MRCP images missing in 4 patients (cilofexor 100 mg, n = 1; cilofexor 30 mg, n = 2; placebo, n = 1).
Abbreviation: BMI, body mass index.
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0.7 mg/dL (0.5, 1.0). The median ELF score and 
liver stiffness by FibroScan were 9.38 (8.91, 9.88) and 
9.4 kPa (6.8, 10.6), respectively, in keeping with mod-
erate to severe fibrosis.
CIloFeXoR ReDUCeS SeRUM alp 
IN a DoSe-DepeNDeNt MaNNeR
At the end of the 12-week double-blind phase, 
significant and dose-dependent reductions in serum 
ALP concentration were observed in patients who 
received cilofexor compared with those who received 
placebo (Table 2 and Fig. 1A). The median (IQR) 
absolute difference from baseline to week 12 in 
serum ALP was −73 U/L (−106, −14) in the cilofexor 
100 mg group (P  = 0.026 versus placebo), −21 U/L 
(−60, 40) in the cilofexor 30 mg group (P  = 0.37 versus 
placebo), and +8 U/L (−40, 118) in the placebo group 
(Fig. 1B). Similarly, relative reductions in serum ALP 
from baseline were greatest in patients who received 
cilofexor. The median (IQR) relative difference from 
baseline to week 12 in serum ALP was −20.5% 
(−30.2, −3.5) in the cilofexor 100 mg group (P  = 0.029 
versus placebo), −6.1% (−17.6, 16.8) in the cilofexor 
30 mg group (P  = 0.32 versus placebo), and +3.4% 
(−7.2, 18.6) in the placebo group (Fig. 1C). Changes 
in serum ALP relative to the ULN are provided in 
Fig. 1C.
taBle 2. Median Relative (%) Changes in liver Biochemistry and Biomarkers from Baseline to Week 12
Cilofexor 100 mg
(n = 22)
Cilofexor 30 mg
(n = 20)
Placebo
(n = 10)
P Values
100 mg Versus 
Placebo
30 mg Versus 
Placebo
ALP −20.5 (−30.2, −3.5) −6.1 (−17.6, 16.8) 3.4 (−7.2, 18.6) 0.029 0.32
UDCA use −18.6 (−35.2, −3.5) −7.8 (−14.3, −1.6) 1.3 (−7.2, 18.6) 0.12 0.27
No UDCA use −20.5 (−27.9, 0.5) 0.0 (−19.2, 21.0) 5.6 (−5.8, 14.7) 0.23 1.00
≥ 25% ALP reduction, % (n/N) 35% (7/20) 5% (1/19) 10% (1/10) 0.21* 1.00*
Absolute ALP change, U/L −73 (−106, −14) −21 (−60, 40) 8 (−40, 118) 0.026 0.37
GGT −30.3 (−47.8, −21.8) −16.3 (−29.7, −7.2) 1.1 (−6.1, 15.0) < 0.001 0.003
ALT −49.4 (−60.7, −22.5) −26.2 (−36.8, 1.7) −12.9 (−22.9, −12.1) 0.009 0.24
AST −42.3 (−51.1, −10.9) −22.5 (−34.7, 20.4) −10.8 (−24.6, 10.5) 0.019 0.32
Total bilirubin 0.0 (−22.1, 29.2) 14.3 (−11.1, 34.5) −11.0 (−27.3, 25.0) 0.58 0.35
Fasting FGF19 −16.6 (−39.0, 13.6) 25.9 (−37.6, 93.7) −43.5 (−51.0, −20.5) 0.16 0.044
Fasting C4 −23.2 (−71.2, 25.7) −30.5 (−50.5, 5.6) 10.0 (−14.3, 29.7) 0.21 0.024
Total bile acids† −38.6 (−55.6, 19.5) 0.0 (−41.5, 57.1) 5.5 (−12.4, 44.6) 0.17 0.67
Primary bile acids‡ −45.1 (−65.8, 18.3) −5.3 (−53.1, 78.3) 4.3 (−35.3, 32.4) 0.15 0.92
Secondary bile acids‡ −39.6 (−62.2, −1.7) 7.4 (−22.4, 16.4) 47.5 (22.6, 92.0) 0.013 0.17
ELF −0.4 (−2.9, 3.0) 0.1 (−1.9, 4.7) 1.2 (−1.9, 2.8) 1.00 0.55
TIMP-1 −8.2 (−13.2, 3.5) 3.8 (−12.7, 17.7) 0.3 (−5.2, 15.5) 0.063 0.73
Hyaluronic acid −4.3 (−20.6, 17.7) 10.0 (−17.7, 56.5) 9.9 (−2.2, 14.3) 0.69 0.59
PIII-NP 2.2 (−6.0, 18.2) −5.4 (−12.8, 22.2) −6.2 (−30.8, 15.5) 0.23 0.30
Liver stiffness by FibroScan −6.7 (−22.2, 13.2) −9.7 (−15.8, 33.8) −5.8 (−27.0, 10.1) 0.76 0.52
CRP −12.2 (−65.7, 40.5) −28.7 (−43.8, 14.8) 8.5 (−23.1, 30.5) 0.56 0.085
Total cholesterol −2.1 (−9.2, 6.1) −0.4 (−8.7, 3.4) 5.4 (−1.3, 9.0) 0.23 0.22
LDL-C 1.5 (−6.6, 10.3) −1.9 (−7.9, 14.8) 0.7 (−7.2, 5.4) 0.60 0.89
HDL-C −10.8 (−17.1, 2.8) 3.4 (−17.3, 7.1) 15.5 (−7.2, 22.4) 0.040 0.12
Triglycerides 8.0 (−13.5, 23.9) −2.0 (-16.1, 6.5) −21.2 (−31.6, 17.4) 0.19 0.33
Glucose 0.0 (−4.3, 9.5) −4.0 (−7.8, 3.2) −3.0 (−8.5, 0.0) 0.23 0.89
Notes: Unless indicated, all data are median relative (%) changes from baseline, and P values are from Wilcoxon rank-sum test. P values 
in boldface are <0.05.
*P value by Fisher exact test.
†Total bile acids by enzymatic assay.
‡Serum bile acid species quantified by LC/MS-MS. UDCA and conjugates removed from secondary bile acids.
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alp ReSpoNSeS aRe 
INDepeNDeNt oF UDCa 
tReatMeNt aND otHeR 
BaSelINe FaCtoRS
An ALP response, defined as at least a 25% relative 
reduction in serum ALP from baseline to week 12, was 
observed more frequently in patients treated with cil-
ofexor 100 mg (35%) than those treated with cilofexor 
30 mg (5.3%) or placebo (10%; P  = 0.21 versus cilofexor 
100 mg). In univariate logistic regression analyses, no 
baseline factor was associated with the likelihood of 
ALP response in cilofexor-treated patients (Supporting 
Table S1). Specifically, age, sex, history of IBD, intra-
hepatic duct involvement on MRCP, ALP and other 
liver biochemistry, fibrosis markers (e.g., ELF, liver 
stiffness), and markers of bile acid homeostasis (e.g., 
FGF19, C4, bile acids) were not associated with ALP 
response. Similarly, UDCA treatment was not associ-
ated with ALP response (odds ratio 0.83; 95% con-
fidence interval 0.17, 4.11). The relative reduction 
in serum ALP between baseline and week 12 in the 
cilofexor 100 mg group was similar between UDCA-
treated (n = 8) and untreated (n = 12) patients (median, 
−18.6% versus −20.5%; P  = 0.85) (Table 2, Fig. 1D).
IMpaCt oF CIloFeXoR 
tReatMeNt oN otHeR 
lIVeR BIoCHeMIStRy aND 
BIoMaRKeRS
Treatment with cilofexor for 12 weeks also led to 
significant reductions in serum ALT, AST, and GGT 
(Table 2, Fig. 2A, and Supporting Fig. S2). From 
FIg. 1. Cilofexor improves serum ALP in patients with PSC. (A) Median (IQR) serum ALP between baseline and week 12 of the 
double-blind phase of the study. (B) Median absolute change in serum ALP from baseline to week 12 of therapy. P values versus placebo 
are according to Wilcoxon rank-sum test. (C) Median (IQR) change in serum ALP relative to the ULN between baseline and week 
12 of therapy. (D) Median relative (percentage) change in serum ALP from baseline to week 12 of therapy (overall and according to 
UDCA treatment). P values versus placebo are according to Wilcoxon rank-sum test.
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baseline to week 12, the median (IQR) relative reduc-
tion in serum ALT was −49.4% (−60.7, −22.5) in the 
cilofexor 100 mg group (P  = 0.009 versus placebo), 
−26.2% (−36.8, 1.7) in the cilofexor 30 mg group 
(P  = 0.24 versus placebo), and −12.9% (−22.9, −12.1) 
in the placebo group. Cilofexor 100 mg also signifi-
cantly reduced serum GGT. At week 12, the median 
(IQR) relative change in serum GGT was −30.3% 
(−47.8, −21.8) in the cilofexor 100 mg group (P  < 0.001 
versus placebo), −16.3% (−29.7, −7.2) in the cilofexor 
30 mg group (P  = 0.003 versus placebo), and +1.1% 
(−6.1, 15.0) in the placebo group. Median (IQR) 
changes from baseline in serum C-reactive protein 
(CRP) were greatest in cilofexor-treated patients 
(100 mg group: −12.2% [−65.7, 40.5]; 30 mg group: 
−28.7% [−43.8, 14.8]), although these differences 
FIg. 2. Effect of cilofexor on liver biochemistry and markers of fibrosis and bile acid homeostasis. (A) Cilofexor 100 mg leads to 
improvement in serum GGT, ALT, AST, and TIMP-1 compared with placebo. P values for cilofexor 100 mg versus placebo are 
according to Wilcoxon rank-sum test. (B) Cilofexor leads to reductions in C4, total bile acids, primary bile acids, and secondary bile 
acids compared with placebo. Total bile acids by enzymatic assay and bile acid species by LC/MS-MS. UDCA and its conjugates 
have been removed from secondary bile acids. P values for cilofexor 100 mg versus placebo are according to Wilcoxon rank-sum test. 
Abbreviations: BA, bile acid; HA, hyaluronic acid.
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were not statistically significant compared with pla-
cebo (+8.5% [−23.1, 30.5]; Table 2).
Liver stiffness and noninvasive markers of fibro-
sis including the ELF score have been associated with 
prognosis in patients with PSC.(17) Between baseline 
and week 12, changes in overall ELF score, PIII-NP, 
hyaluronic acid, and liver stiffness did not differ between 
treatment groups (Table 2). However, in patients treated 
with cilofexor 100 mg, a trend toward reduced serum 
levels of TIMP-1 was observed (median, −8.2% versus 
+0.3% in the placebo group; P  = 0.063).
pHaRMaCoDyNaMIC MaRKeRS 
oF BIle aCID HoMeoStaSIS
We also evaluated markers indicative of FXR 
agonism by cilofexor treatment affecting bile acid 
homeostasis. Compared with placebo treatment, fast-
ing plasma levels of FGF19 were increased in patients 
treated with cilofexor 30 mg, but not cilofexor 100 mg 
(Table 2 and Fig. 2B). Although serum levels of C4, 
the metabolite produced subsequent to the conver-
sion of cholesterol to 7-alpha-hydroxycholesterol by 
FIg. 3. Cilofexor 100 mg lowers serum bile acids, but does not alter bile acid composition. (A) Absolute levels of serum bile acid 
species before and after 12 weeks of treatment with cilofexor 100 mg daily. UDCA and its conjugates have been removed. (B) Relative 
contribution of serum bile acid species before and after 12 weeks of treatment with cilofexor 100 mg daily. UDCA and its conjugates 
have been removed. Abbreviations: CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; 
GCDCA: glycochenodeoxycholic acid; GDCA, glycolithocholic acid; GLCA, glycolithocholic acid; LCA, lithocholic acid; TCA: 
taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TLCA, taurolithocholic acid.
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CYP7A1, declined in both cilofexor treatment groups, 
the total, primary, and secondary bile acids decreased 
only during therapy with cilofexor 100 mg. Compared 
with the placebo group, median relative reductions in 
C4 (+10.0% versus −23.2%; P  = 0.21), total bile acids 
(+5.5% versus −38.6%; P  = 0.17), primary bile acids 
(+4.3% versus −45.1%; P  = 0.15), and secondary bile 
acids (+47.5% versus −39.6%; P  = 0.013) were greater 
in patients treated with cilofexor 100 mg (Table 2 and 
Fig. 2B).
Considering the observed reductions in bile acids 
among patients treated with cilofexor 100 mg, we 
analyzed changes in the concentrations of the various 
bile acid species to identify the main drivers of these 
reductions. First, we observed that more than 50% of 
the bile acid pool at baseline consisted of the conju-
gated primary bile acids, glycocholic acid (GCA) and 
glycochenodeoxycholic acid (GCDCA). At week 12, 
significant reductions in the absolute concentrations 
of most bile acid species were observed (Fig. 3A); 
however, no substantial changes in bile acid compo-
sition were noted (Fig. 3B). For example, the median 
(IQR) relative changes of GCA and GCDCA from 
baseline to week 12 in the cilofexor 100 mg group 
were −58.1% (−68.1, −20.8) and −41.7% (−69.8, 0.2), 
respectively (P  = 0.03 and P  = 0.18 versus placebo). 
These data suggest that the effects of cilofexor on 
serum bile acid concentrations are largely due to inhi-
bition of bile acid synthesis.
CoNSISteNCy oF ReSpoNSe 
WItH CIloFeXoR
To evaluate the consistency of response with cil-
ofexor treatment, we evaluated the relative changes 
in liver biochemistry and other biomarkers according 
to achievement of an ALP response. Compared with 
nonresponders (n = 31), responders to cilofexor (n = 8) 
had greater relative reductions in GGT, ALT, and 
AST; total, primary, and secondary bile acids; TIMP-
1; hyaluronic acid; and CRP (Fig. 4).
SaFety aND toleRaBIlIty oF 
CIloFeXoR tReatMeNt
Treatment with cilofexor for 12 weeks was gen-
erally well tolerated. In total, 5 patients did not 
complete the study drug treatment: 3 patients 
(14%) discontinued cilofexor 100 mg due to AEs 
(n = 1 each of pruritus, acute kidney injury, and ele-
vated ALP); 1 patient (5%) discontinued cilofexor 
30 mg due to patient decision; and 1 placebo-treated 
FIg. 4. Relative changes in liver biochemistry, markers of fibrosis, and other biomarkers according to achievement of an ALP response, 
defined as at least a 25% relative reduction in serum ALP from baseline to week 12, in cilofexor-treated patients. Responder subgroup 
includes 7 patients treated with cilofexor 100 mg and 1 patient treated with cilofexor 30 mg. P values are according to Wilcoxon rank-
sum test. Abbreviations: BA, bile acid; HA, hyaluronic acid.
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patient (10%) discontinued due to elevated liver bio-
chemistry. AEs, which were generally grade 1 or 2 
in severity and deemed not to be treatment-related 
by the investigator, were similar between treatment 
groups (Table 3). Treatment-emergent pruritus 
occurred in 36% (8 of 22) of patients treated with 
cilofexor 100 mg, 25% (5 of 20) treated with cil-
ofexor 30 mg, and 60% (6/10) of patients treated 
with placebo. Treatment-emergent, grade 2-3 pruri-
tus was observed in 14% (3 of 22) of patients treated 
with cilofexor 100 mg, 20% (4 of 20) with 30 mg, 
and 40% (4 of 10) with those who received placebo. 
Three SAEs occurred, all in patients treated with 
cilofexor 100 mg (rib fracture, diarrhea/dehydration, 
and acute kidney injury), but none were deemed 
treatment-related by the investigator. No deaths 
occurred during the study.
Most patients had at least one laboratory abnor-
mality, most of whom were grade 1 or 2 in severity 
(Supporting Table S2). Overall, the most common 
grade 3 or 4 laboratory abnormalities were elevated 
liver biochemistry results, specifically, elevated AST 
(13.5%, 7 of 52), ALT (9.6%, 5 of 52), and ALP 
(7.7%, 4 of 52). A similar proportion of patients met 
prespecified criteria for withholding of study medi-
cation due to abnormal liver biochemistry: cilofexor 
100 mg, 9.1% (2 of 22); cilofexor 30 mg, 5.0% (1 of 20); 
and placebo, 10.0% (1 of 10). Changes in serum total 
cholesterol, LDL-C, and triglycerides did not differ 
between cilofexor-treated and placebo-treated patients 
(Table 2). However, a median relative reduction 
in HDL-C of 10.8% was observed in the cilofexor 
100 mg group compared with an increase of 15.5% in 
the placebo group (P  = 0.040).
Discussion
In this double-blind, placebo-controlled, random-
ized study in patients without cirrhosis with large-
duct PSC, the nonsteroidal FXR agonist cilofexor was 
safe, well tolerated, and improved biochemical mark-
ers of cholestasis and inflammation. The main find-
ings of this study included significant dose-dependent 
reductions in serum concentrations of ALP, GGT, 
ALT, and AST within 12 weeks of treatment with 
cilofexor compared with placebo. The effects on ALP 
were independent of UDCA use, present in nearly 
half of the included patients. These data confirm that 
the mechanism of action of cilofexor is distinct from 
that of UDCA, which does not have relevant FXR 
agonistic activity. In this regard, the 100-mg dose of 
cilofexor led to reductions in serum C4 and plasma 
bile acids, but did not alter bile acid composition, 
which is consistent with inhibition of bile acid bio-
synthesis through suppression of CYP7A1 activity. 
However, fasting plasma levels of FGF19 did not 
increase at this dose, as would have been expected due 
to activation of intestinal FXR. This finding is due to 
our assessment of FGF19 in the predose, fasted state. 
Indeed, data from healthy volunteers has confirmed 
a rapid, dose-dependent increase in FGF19 levels 
when measured serially following cilofexor adminis-
tration.(18) Interestingly, a recent study that included 
healthy volunteers administered a different nonsteroi-
dal FXR agonist (Px-102), suggesting that these com-
pounds may reduce bile acid synthesis independent 
of FGF19 production.(19) Finally, although changes 
taBle 3. treatment–emergent aes Reported for at least 2 
patients in any treatment group by preferred term
Preferred Term
Cilofexor
100 mg
(n = 22)
Cilofexor
30 mg
(n = 20)
Placebo
(n = 10)
Number (%) of patients with 
any AE
18 (81.8%) 13 (65.0%) 10 (100.0%)
Pruritus 8 (36.4%) 5 (25.0%) 6 (60.0%)
Nasopharyngitis 5 (22.7%) 5 (25.0%) 2 (20.0%)
Abdominal pain upper 3 (13.6%) 2 (10.0%) 1 (10.0%)
Fatigue 3 (13.6%) 2 (10.0%) 2 (20.0%)
Abdominal discomfort 2 (9.1%) 0 1 (10.0%)
Abdominal distension 2 (9.1%) 0 1 (10.0%)
Blood ALP increased 2 (9.1%) 0 1 (10.0%)
Constipation 2 (9.1%) 0 0
Diarrhea 2 (9.1%) 1 (5.0%) 0
Dizziness 2 (9.1%) 1 (5.0%) 0
Electrocardiogram 
abnormal
2 (9.1%) 0 0
Upper respiratory tract 
infection
2 (9.1%) 0 1 (10.0%)
Viral infection 2 (9.1%) 0 0
ALT increased 1 (4.5%) 0 2 (20.0%)
Back pain 1 (4.5%) 2 (10.0%) 0
Headache 1 (4.5%) 4 (20.0%) 2 (20.0%)
Muscle spasms 1 (4.5%) 2 (10.0%) 0
Pyrexia 1 (4.5%) 2 (10.0%) 0
AST increased 0 0 2 (20.0%)
Nausea 0 1 (5.0%) 3 (30.0%)
Note: Adverse events were coded according to MedDRA Version 
20.1.
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in liver stiffness by FibroScan and ELF scores were 
not observed, patients treated with cilofexor 100 mg 
had a trend toward reduced serum levels of the pro- 
fibrogenic cytokine TIMP-1, suggesting a potential 
antifibrotic effect of this treatment. Future trials of 
longer duration with liver histology will be necessary 
to confirm this finding.
A significant finding of this study was the 
dose-dependent reduction in serum ALP observed 
in cilofexor-treated patients. Following 12 weeks 
of therapy, 35% of patients treated with cilofexor 
100 mg had an ALP response, defined as at least a 25% 
relative reduction from baseline, compared with only 
10% of placebo-treated patients. Consistent with 
improved cholestasis, responders to cilofexor had 
greater improvements in other markers of cholesta-
sis (e.g., GGT, total bile acids, primary bile acids), 
hepatic inflammation (e.g., ALT, AST, CRP), and 
fibrosis (e.g., TIMP-1, hyaluronic acid). Although 
the consistency of these responses supports the effi-
cacy of cilofexor, long-term studies are necessary to 
confirm that reduction in the surrogate endpoint of 
serum ALP is associated with improved clinical out-
comes. Indeed, given the chronicity of PSC and the 
lack of accepted biomarkers associated with disease 
progression, endpoints that define clinical utility 
of any pharmacologic intervention in PSC remain 
undefined.(20,21) Based on recent guidance, a com-
posite endpoint that includes serum ALP response 
along with assessment of fibrosis (e.g., through elas-
tography or biopsy) may be sufficient for this pur-
pose.(21) Although the association between fibrosis 
and clinical outcomes in PSC is clear, data describ-
ing the link between ALP reduction and clini-
cal events are evolving. For example, retrospective 
cohort studies, including post hoc analyses of ran-
domized trials evaluating UDCA, have shown that 
serum ALP at baseline and 1 year after diagnosis, 
as well as improvement over time, are associated 
with better clinical outcomes.(6-9,22,23) For example, 
in the Scandinavian UDCA trial, ALP normaliza-
tion and/or a 40% or more relative reduction at 
1 year was associated with a reduced risk of death, 
transplantation, or cholangiocarcinoma, regardless 
of UDCA use.(7) The 40% reduction threshold used 
in the Scandinavian study was chosen based on data 
from PBC, whereas other thresholds were not eval-
uated. However, in a large observational study of 
692 patients with PSC in the Netherlands (Epi PSC 
PBC), a 25% relative reduction (versus no change) 
in serum ALP 1 year after diagnosis was associ-
ated with a greater than 25% relative reduction in 
the risk of liver transplantation or PSC-related 
death over a median follow-up of 100 months.(6) 
These findings suggest that serum ALP could be 
an important prognostic marker in PSC, and that 
interventions that reduce ALP may have meaningful 
clinical benefit.
Previous studies of FXR agonists in patients 
with PBC and NASH have reported pruritus and 
changes in serum lipids as potential drawbacks to 
this class of agents.(22,24) In the current study, cil-
ofexor was safe and well tolerated. Overall, the 
incidence of treatment-emergent AEs was simi-
lar between cilofexor-treated and placebo-treated 
patients. The most frequently reported AE across 
the three study groups—including placebo—was 
pruritus, confirming the importance of this symp-
tom in patients with PSC. Over 12 weeks of treat-
ment, moderate to severe (grade 2-3) pruritus was 
observed in 14%-20% of cilofexor-treated patients 
compared with 40% of those who received placebo. 
One patient treated with cilofexor 100 mg discon-
tinued study medication due to pruritus, which 
occurred soon after initiating therapy. Larger and 
longer-term studies will be necessary to fully char-
acterize the potential effect of cilofexor on pruri-
tus in PSC, which may differ from steroidal, bile 
acid–derived FXR ligands such as obeticholic acid. 
Finally, although no changes were observed in total 
cholesterol or LDL-C, patients treated with cil-
ofexor 100 mg experienced an approximately 10% 
decrease in HDL-C over 12 weeks of treatment. 
The relevance of this change with respect to cardio-
vascular risk warrants further evaluation.
Our study has several limitations. First, patients 
with cirrhosis were excluded because the pharmaco-
kinetics of cilofexor in the setting of cirrhosis were 
unknown at the time of study initiation. However, 
current data suggest that patients with compen-
sated cirrhosis have minimal alterations in the 
pharmacokinetic and pharmacodynamic profiles of 
cilofexor compared with healthy controls.(18) Given 
the absence of approved pharmacologic therapy for 
PSC, targeting those at risk of progressing to cir-
rhosis remains an important area of unmet need. 
Additional trials will evaluate the safety and efficacy 
of cilofexor in patients with cirrhosis due to PSC, as 
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are currently ongoing for nonalcoholic steatohepati-
tis (NCT03449446). A second limitation is that we 
included only patients with classic large-duct PSC. 
The generalizability of our findings to other pop-
ulations, including patients with small-duct PSC, 
overlap syndrome of PSC with autoimmune hepa-
titis, immunoglobulin-4-related sclerosing cholangi-
tis, and pediatric patients, is unclear. Moreover, our 
study cohort had a lower prevalence of IBD than 
the broader PSC population, and all patients with 
IBD had quiescent disease. Reassuringly, no patient 
had exacerbation of their IBD or developed new 
onset IBD during the 12-week study. Indeed, pre-
clinical studies have suggested that FXR agonism 
improves intestinal barrier function in animal mod-
els of fibrosis and IBD. These observations require 
clinical evaluation.
In conclusion, this randomized phase II study 
demonstrates that the nonsteroidal FXR agonist cil-
ofexor was well tolerated and improved markers of 
cholestasis, liver biochemistry, C4, and serum bile 
acids in patients with PSC. These effects were inde-
pendent of UDCA use, thereby pointing to a dis-
tinct and potentially complementary mechanism of 
action. Assessment of whether cilofexor affects clin-
ically relevant endpoints associated with PSC, such 
as progression to cirrhosis, hepatic decompensation, 
cholangiocarcinoma, transplantation, and mortality, 
await longer-term controlled studies.
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